Deciphera Pharmaceuticals (STU:D05) Beginning Cash Position : €76.8 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Deciphera Pharmaceuticals Beginning Cash Position?

Deciphera Pharmaceuticals's Beginning Cash Position for the quarter that ended in Mar. 2024 was €76.8 Mil.

Deciphera Pharmaceuticals's quarterly Beginning Cash Position increased from Sep. 2023 (€76.3 Mil) to Dec. 2023 (€99.1 Mil) but then declined from Dec. 2023 (€99.1 Mil) to Mar. 2024 (€76.8 Mil).

Deciphera Pharmaceuticals's annual Beginning Cash Position declined from Dec. 2021 (€120.3 Mil) to Dec. 2022 (€82.2 Mil) and declined from Dec. 2022 (€82.2 Mil) to Dec. 2023 (€59.4 Mil).

Deciphera Pharmaceuticals Beginning Cash Position Historical Data

The historical data trend for Deciphera Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deciphera Pharmaceuticals Beginning Cash Position Chart

Deciphera Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

264.39

98.90

120.27

82.19

59.37

Deciphera Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															60.47	105.81	76.27	99.12	76.83

Deciphera Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Deciphera Pharmaceuticals Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Deciphera Pharmaceuticals's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Deciphera Pharmaceuticals (STU:D05) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (STU:D05) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

DCPH:USA D05:Germany

Address

200 Smith Street, Waltham, MA, USA, 02451

Website

https://www.deciphera.com

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

Deciphera Pharmaceuticals (STU:D05) Headlines

No Headlines